Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Mycobutin 150 Mg Caps 100 By Pfizer Pharma

Image 0 of Mycobutin 150 Mg Caps 100 By Pfizer PharmaImage 1 of Mycobutin 150 Mg Caps 100 By Pfizer Pharma

Mycobutin 150 Mg Caps 100 By Pfizer Pharma

Call for Price

Mycobutin 150 Mg Caps 100 By Pfizer Pharma This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD1533371/RXB10033733
Size : 100
Selling UoM : EA
NDC: 00013-5301-17
UPC Barcode : 300135301172
Supplier:0050000308 PFIZER PHARM
Supplier Material : 2061
Generic Code : 018766 RIFABUTIN ORAL CAPSULE 150 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded RX

Have a question?

  Call for Price

Product Description.:

MYCOBUTIN, PHARMACIA & UPJOHN
capsule , brown , oblong oblong
White inkOpaque

MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactive ingredients microcrystalline cellulose, magnesium stearate, red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink.

Rifabutin is a red-violet powder soluble in chloroform and methanol, sparingly soluble in ethanol, and very slightly soluble in water (0.19 mg/mL). Its log P value (the base 10 logarithm of the partition coefficient between n-octanol and water) is 3.2 (n-octanol/water).

INDICATIONS

MYCOBUTIN Capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.


SIDE EFFECTS

MYCOBUTIN Capsules were generally well tolerated in the controlled clinical trials. Discontinuation of therapy due to an adverse event was required in 16% of patients receiving MYCOBUTIN compared to 8% of patients receiving placebo in these trials. Primary reasons for discontinuation of MYCOBUTIN were rash (4% of treated patients), gastrointestinal intolerance (3%), and neutropenia (2%).